PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

SATELLITE SYMPOSIA


Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2022 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Mon - Aug 15      Tue - Aug 16      Wed - Aug 17      Thu - Aug 18   

TUESDAY, AUGUST 16

7:15 - 8:15 AM
SATELLITE SYMPOSIUM
ARE HIGHER FACTOR LEVELS A RISING CONSIDERATION WHEN SELECTING A HEMOPHILIA TREATMENT? (SPONSORED BY NOVO NORDISK, INC. )
Chicago Ballroom VI

This program will discuss the clinical relevance of reaching high factor activity levels in patients with hemophilia. An increased risk of bleeding episodes exists with time spent at low factor activity levels, and the World Federation of Hemophilia recognizes the importance of high factor activity levels and maintaining hemostasis in patients with hemophilia. The pharmacokinetic and clinical characteristics of products used to treat patients with hemophilia will also be presented. Click Here to take the post survey.



NEW CLINICAL DATA FOR PROPHYLAXIS IN VON WILLEBRAND DISEASE AND HEMOPHILIA A (SPONSORED BY OCTAPHARMA AG)
Chicago Ballroom IX-X

Join Jill Johnsen, Robert Sidonio and Craig Kessler for this symposium putting prophylaxis under the spotlight and presenting new clinical data and ongoing investigations for its use in people with von Willebrand disease (VWD) and hemophilia A. The potential for prophylaxis to offer optimal bleed protection in people with VWD will be discussed, supported by new clinical data from a recently completed prospective trial of prophylaxis with a von Willebrand factor/coagulation factor VIII (VWF/FVIII) concentrate. Next generation sequencing (NGS) is a powerful tool whose use to characterize VWF mutations may improve VWD diagnosis and management. In people with severe hemophilia A, prophylaxis is widely accepted as the standard of care, and should be personalized to the patients needs. However, the lack of head-to-head studies of different FVIII products makes it challenging to make informed treatment decisions. Insights into the relative effects of different products can be obtained through indirect comparisons using validated statistical methodology. The results of such a comparison of personalized prophylaxis studies in hemophilia A will be presented and discussed. The differential binding capacity for rFVIII concentrates could have implications in platelet biology and new scientific data will be presented.


8:30 - 9:45 AM
PLENARY SESSION
PATIENT CENTERED OUTCOMES
Chair/Organizer: Cathy Hayward, Vinai Bhagirath
Sheraton Ballroom IV-V


INTRODUCTION VIDEO.


8:30

PATIENT CENTERED OUTCOMES RESEARCH - PCORI METHODOLOGY
Mark Skinner. Institute for Policy Advancement Ltd.


8:50

PATIENT CENTERED RESEARCH - THROMBOSIS
Elliott Haut. Johns Hopkins Medicine


9:10

PATIENT CENTERED RESEARCH - HEMOSTASIS
Diane Nugent. CHOC Children's Hospital


9:30

Q&A.

9:45 - 10:45 AM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB

Coffee Break sponsored by Spark Therapeutics, Inc.



A1. ANTICOAGULATION CLINICS


101

LABORATORY MIMICS: A POTENT LUPUS COFACTOR EFFECT MASQUERADING AS A COAGULATION FACTOR X INHIBITOR IN A PATIENT WITH A B-CELL NEOPLASM
Angela M Verdoni, PhD, DABMGG1, Nicoletta Machin, DO2, 3, Michael Meyer, MSc1, Donald Woytowitz, MD2, 3, Margaret Ragni, MD, MPH2, 3, Franklin Bontempo, MD1, 2, 3, Jansen Seheult, MB BCh BAO, MSc, MD1, 4, Irina Chibisov, MD1, 5. 1Vitalant Specialty Labs, Pittsburgh, PA, USA. 2Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 3Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA. 4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 5Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA


A2. PLATELET ACTIVATION AND BIOCHEMISTRY


102

IMER, A NATURALLY OCCURRING MERTK SPLICE VARIANT, INHIBITS PLATELET AGGREGATION BY TRAPPING GAS6
Adam Kidwell1, 2, Stephanie Springborn1, Peter Newman1, Jorge DiPaola3, Deborah DeRyckere4, 5, Douglas K Graham4, 5, Brian R Branchford1, 2. 1Versiti Blood Research Institute, Wauwatosa, WI, USA. 2Medical College of Wisconsin, Department of Pediatrics, Wauwatosa, WI, USA. 3Washington University School of Medicine, Department of Pediatrics, St. Louis, MO, USA. 4Aflac Cancer a Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. 5Emory University School of Medicine, Department of Pediatrics, Atlanta, GA, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


103

UNIQUE CASE OF REFRACTORY THROMBOTIC THROMBOCYTOPENIC PURPURA DUE TO UNDIAGNOSED SJOGREN'S SYNDROME
Syed Kamran, Mimi Baber, Joud Zakhour. University of Kansas, Wichita, KS, USA


104

THE EFFECT OF CHRONIC LYMPHOCYTIC LEUKEMIA IN HOSPITALIZED IMMUNE THROMBOCYTOPENIA PATIENTS: A NATIONWIDE ANALYSIS.
Ekrem Turk1, Khaldun Obeidat1, Yasin Goksu2. 1John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA. 2University of Illinois at Chicago, Department of Pathology, Chicago, IL, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


105

DEFINING THE IMPACT OF SOCIAL DRIVERS ON HEALTH OUTCOMES FOR PEOPLE WITH INHERITED BLEEDING DISORDERS
Karina Lopez1, Keri Norris1, Marci Hardy1, Leonard A. Valentino1, 2. 1National Hemophilia Foundation, New York, NY, USA. 2Rush University, Chicago, IL, USA


106

EVALUATION OF INHIBITORS EFFECT ON PLASMIN'S AMIDOLYTIC AND FIBRINOLYTIC ACTIVITY USING S-2251 AND ANNULAR FIBRIN CLOT ASSAYS
Tanmaye Nallan Chakravarthula1, 2, Liliana Patino1, Ziqian Zeng1, 2, Nathan J. Alves1, 2. 1Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. 2Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


107

ASSOCIATION OF HYPONATREMIA WITH CLINICAL OUTCOMES IN PATIENTS ADMITTED WITH ACUTE PULMONARY EMBOLISM: ANALYSIS OF THE NATIONAL INPATIENT SAMPLE
VAISHALI DEENADAYALAN MD, DENNIS DANSO KUMI MD, BIRJU PATEL MD. John H Stroger Jr Hospital of Cook County, Chicago, IL, USA


108

DEFINING THE EPITOPE SPECIFICITY OF THE EARLY IGM RESPONSE TO FACTOR VIII IN HEMOPHILIA A MICE
Saeyeon Ju1, Wallace Hunter Baldwin2, Courtney Cox2, Shannon L Meeks2, Seema R Patel2. 1Emory University, Atlanta, GA, USA. 2Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University School of Medicine, Atlanta, GA, USA


109

PROPHYLAXIS WITH RECOMBINANT VON WILLEBRAND FACTOR IN PATIENTS WITH TYPE 3 VON WILLEBRAND DISEASE: POST HOC ANALYSIS FROM A PHASE 3 TRIAL
Frank W. G. Leebeek1, Miguel Escobar2, Andreas Tiede3, Michael Wang4, Bulent Zulfikar5, Scarlett Wang6, Yi Wang6, Gulden Ozen6. 1Department of Hematology, Erasmus MC, University Medical Center, Rotterdam, Netherlands. 2University of Texas Health Science Center at Houston, Houston, TX, USA. 3Hannover Medical School, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany. 4Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 5Department of Pediatric Hematology/Oncology, Istanbul University Oncology Institute, Istanbul, Turkey. 6Takeda Development Center Americas, Inc, Cambridge, MA, USA


110

PATHOLOGIST-DIRECTED REFLEXIVE EVALUATION OF PROLONGED CLOTTING TIMES: A NATIONAL REFERENCE LABORATORY EXPERIENCE.
Karen A Moser1, 2, Ming Y Lim3, Kristi J Smock1, 2. 1Department of Pathology, University of Utah, Salt Lake City, UT, USA. 2ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA. 3Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA


111

THE IMPACT OF NOVEL HEMOPHILIA TREATMENT PRODUCTS ON INHIBITOR TESTING FOR THE COMMUNITY COUNTS REGISTRY FOR BLEEDING DISORDERS SURVEILLANCE: AN UPDATE
Amanda B. Payne, Connie H. Miller, Jennifer Driggers, Brian Boylan, Bonnie Werner, Glenn P. Niemeyer, Vanessa R. Byams, Karon Abe, Christopher J. Bean. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA


112

INTERIM SUBGROUP ANALYSIS OF HEMOPHILIA A SEVERITY ON THE EFFECTIVENESS AND SAFETY OF DAMOCTOCOG ALFA PEGOL FROM THE REAL-WORLD OBSERVATIONAL HEM-POWR STUDY
Mark Reding1, Maria Teresa Alvarez Roman2, Martin Sanabria3, Giancarlo Castaman4, Maissaa Janbain5, Tadashi Matsushita6, Karina Meijer7, Kathrin Schmidt8, Johannes Oldenburg9. 1University of Minnesota Medical Center, Minneapolis, MN, USA. 2Hospital Universitario La Paz, Madrid, Spain. 3Bayer, Basel, Switzerland. 4Careggi University Hospital, Florence, Italy. 5Tulane School of Medicine, New Orleans, LA, USA. 6Nagoya University Hospital, Nagoya, Japan. 7University Medical Center Groningen, Groningen, Netherlands. 8Bayer, Berlin, Germany. 9University Clinic Bonn, Bonn, Germany


113

A CASE OFLYMPHOMA-ASSOCIATEDACQUIREDVON WILLEBRAND SYNDROME RESPONSIVE TO SPLENECTOMY
Natasha S. Rupani1, Fatima Khadadah1, Martina Trinkaus2, Jordan Scott1, Jerry Teitel3, Michelle Sholzberg4. 1Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada. 2Division of Hematology/Oncology, Department of Medicine, University of Toronto, Toronto, ON, Canada. 3Division of Hematology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. 4Division of Hematology/Oncology, Departments of Medicine and Laboratory Medicine a Pathobiology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada


A7. PATHOPHYSIOLOGY OF THROMBOSIS


114

THROMBO-INFLAMMATORY BIOMARKERS OF CARDIORENAL SYNDROME IN PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS IN END STAGE RENAL DISEASE
Pranathi Karumanchi, Jawed Fareed, Vinod Bansal, Fakiha Siddiqui, Debra Hoppensteadt, Bulent Kantarcioglu. Loyola University Medical Center, Maywood, IL, USA


A8. ANTITHROMBOTIC THERAPY


115

DABIGATRAN REVERSAL WITH IDARUCIZUMAB IN A PEDIATRIC PATIENT AND SUMMARY OF THE CLINICAL STUDY IN ADULT PATIENTS WITH LOW BODY WEIGHTS (
Leonardo R. Brandao1, Joanne van Ryn2, Ildar Nurmeev3, Igor Tartakovsky2, Corinna Miede4, Charles V. Pollack Jr5, Manuella Albisetti6. 1The Hospital for Sick Children, Toronto, ON, Canada. 2Boehringer Ingelheim International GmbH, Ingelheim, Germany. 3Pediatric Hospital Kazan Medical University, Kazan, Russia. 4mainanalytics GmbH, Sulzbach/Taunus, Germany. 5University Mississippi School of Medicine, Jackson, MS, USA. 6University Children's Hospital, Zurich, Switzerland


116

EFFECT OF THREE FACTOR XA INHIBITORS ON A SUBSET OF COMMON COAGULATION ASSAYS
Ronda A Crist1, Daniel A Stephens1, George M Rodgers1, 2, 3, Karen A Moser1, 2, Kristi J Smock1, 2. 1ARUP Laboratories Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA. 2Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. 3Division of Hematology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA


117

USP STANDARDIZED MIXTURES OF BOVINE, OVINE AND PORCINE HEPARIN EXHIBIT COMPARABLE BIOLOGIC EFFECTS TO REFERENCED SINGLE SOURCED HEPARINS AND MAY BE INTERCHANGEABLE
Guy Olson, Walter Jeske, Omer Iqbal, Ambar Farooqui, Fakiha Siddiqui, Debra Hoppensteadt, Ahmed Kouta, Jawed Fareed. Loyola University Chicago - Cardiovascular Research Institute - Section of Hemostasis and Thrombosis, Maywood, IL, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


118

HOW MEDICAL EXPERIENCES AND THOUGHTS OF PERSONS WITH INHERITED BLEEDING DISORDERS AND THEIR PARENTS/GUARDIANS ARE INFLUENCED BY THE CORONA PANDEMIC - AN INTERNATIONAL COMPARISON
Maria E Santaella1, Michelle L Witkop1, Kate Khair2, Mabel Crescioni3, Cynthia Nichols1, Sylvia von Mackensen4. 1National Hemophilia Foundation, New York, NY, USA. 2The Haemophilia Society, London, United Kingdom. 3Hemophilia Federation of America, Washington, DC, USA. 4Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

10:45 - 11:45 AM
SHORT TALKS
SHORT TALKS - ANTICOAGULATION AND OTHER THERAPIES
Chair/Organizer: Anna Parks, Julie Jaffray
Sheraton Ballroom IV-V


10:45

ADVERSE EVENTS IN LOW VERSUS NORMAL BODY WEIGHT PATIENTS PRESCRIBED APIXABAN OR RIVAROXABAN FOR ATRIAL FIBRILLATION.
Deborah DeCamillo1, Brian Haymart1, Xiaowen Kong1, Scott Kaatz2, Mona Ali3, Geoffrey Barnes1, Scott Kaatz4. 1University of Michigan, Ann Arbor, MI, USA. 2Henry Ford Health System, Detroit, MI, USA. 3Beaumont Health, Royal Oak, MI, USA. 4Hurley Medical Center, Flint, MI, USA


10:57

ANTI-FACTOR XA-BASED RISK STRATIFICATION FOR PATIENTS RECEIVING THERAPEUTIC ENOXAPARIN IS ASSOCIATED WITH INCREASED RISK OF RECURRENT/PROGRESSIVE THROMBOSIS AND HEMORRHAGE
Emily C Drake1, Wallace Bourgeois1, 2, Juliann Duzan1, Nan Chen1, 2, Nikitha Ramesh1, Wendy B London1, 2, Riten Kumar1, 2. 1Boston Children's Hospital, Boston, MA, USA. 2Dana Farber Cancer Institute, Boston, MA, USA


11:09

SAFETY OF THE CONCURRENT USE OF FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE WITH ANDEXANET ALFA FOR REVERSAL OF FACTOR XA INHIBITOR-RELATED BLEEDING: A RETROSPECTIVE CASE SERIES PARDIS NIAMI, PHARMD, AND TODD E. H. HECHT, MD, FACP, SFHM
Pardis Niami, Todd Hecht. Hospital of the University of Pennsylvania, Philadelphia, PA, USA


11:21

FOCUS GROUP-GUIDED DEVELOPMENT OF A NOVEL BLEEDING QUALITY OF LIFE PATIENT-REPORTED OUTCOME MEASURE FOR OLDER ADULTS
Anna L. Parks1, Stacey L. Slager1, Margaret C. Fang2, Mark A. Supiano1, Patti P. Katz2, Daniel M. Witt1. 1University of Utah, Salt Lake City, UT, USA. 2University of California, San Francisco, San Francisco, CA, USA


11:33

MANAGEMENT OF POTENTIAL DRUG-DRUG INTERACTIONS WITH NIRMATRELVIR-RITONAVIR AND ORAL ANTICOAGULANTS: A CASE SERIES
Aaron S. Wilson1, Sara R. Vazquez1, 2, Daniel M. Witt1, 2. 1University of Utah College of Pharmacy Department of Pharmacotherapy, Salt Lake City, UT, USA. 2University of Utah Health Community Thrombosis Clinic, Salt Lake City, UT, USA


SHORT TALKS - BLEEDING I
Chair/Organizer: Robert Sidonio, Yasmina Abajas
Sheraton Ballroom I-III


10:45

IMPACT OF ANEMIA ON VON WILLEBRAND FACTOR AND FACTOR VIII IN TYPE 1 VON WILLEBRAND DISEASE AND MILD HEMOPHILIA
Maria E. Carter Febres, Cristina Tarango, Matthew Fenchel, Jennifer Pomales, Eric Mullins. Cincinnati Children's Hospital, Cincinnati, OH, USA


10:57

PROPHYLAXIS WITH RECOMBINANT VON WILLEBRAND FACTOR IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE: PHASE 3 TRIAL RESULTS
Frank W. G. Leebeek1, Flora Peyvandi2, Miguel Escobar3, Andreas Tiede4, Giancarlo Castaman5, Joan Gu6, Bjorn Mellgard7, Bruce Ewenstein7, Gulden Ozen7. 1Erasmus Medical Center, University Medical Center, Rotterdam, Netherlands. 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca, Milan, Italy. 3University of Texas Health Science Center at Houston, Houston, TX, USA. 4Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. 5Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy. 6Takeda Development Center Americas, Inc, Lexington, MA, USA. 7Takeda Development Center Americas, Inc, Cambridge, MA, USA


11:09

INHIBITORS OF INORGANIC POLYPHOSPHATE AND NUCLEIC ACIDS LEAD TO DECREASED THROMBIN GENERATION IN TRAUMA PATIENTS
Taleen A. MacArthur1, Julie Goswami1, Sreeparna Vappala 2, John Zietlow1, Stephanie A. Smith3, James H. Morrissey 3, Scott P. Zietlow1, Grant M. Spears1, Kent R. Bailey1, Jing-fei Dong4, Rosemary A. Kozar5, Jayachandran N. Kizhakkedathu 2, Myung S. Park1. 1Mayo Clinic, Rochester, MN, USA. 2University of British Columbia, Vancouver, BC, USA. 3University of Michigan School of Medicine , Ann Arbor, MI, USA. 4University of Washington School of Medicine, Seattle, WA, USA. 5Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA


11:21

EFANESOCTOCOG ALFA EXHIBITS VON WILLEBRAND FACTOR-INDEPENDENT PHARMACOKINETICS IN SEVERE HEMOPHILIA A: A POST HOC ANALYSIS FROM PHASE 1/2A STUDIES
Janice/M. Staber1, Toshko/J. Lissitchkov2, Barbara/A. Konkle3, Amy/D. Shapiro4, Doris/V. Quon5, Roshni Kulkarni6, Melinda Hamilton7, Ekta/S. Chhabra8, Suresh Katragadda8, Arman Altincatal9, Annemieke Willemze10, Jennifer Dumont9, Margaret/V. Ragni11. 1University of Iowa Stead Family Children, Iowa City, IA, USA. 2Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia Bulgaria. 3Washington Center for Bleeding Disorders and the University of Washington, Seattle, WA, USA. 4Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. 5Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, USA. 6Michigan State University, East Lansing, MI, USA. 7Swedish Orphan Biovitrum AB, Stockholm Sweden. 8Sanofi, Waltham, MA, USA. 9Sanofi, Cambridge, MA, USA. 10Sanofi, Amsterdam, MA, Netherlands. 11Department of Medicine, University of Pittsburgh, and the Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA


SHORT TALKS - LABORATORY ADVANCES
Chair/Organizer: Andrew Goodwin , Cecily Allen
Chicago Ballroom VII


10:45

FACTOR VIII LEVELS AND INTERNATIONAL SOCIETY ON THROMBOSIS AND HEMOSTASIS (ISTH) DISSEMINATED INTRAVASCULAR COAGULATION (DIC) SCORES DO NOT DISCRIMINATE COAGULOPATHY OF LIVER DISEASE FROM DIC
Cecily Allen1, Marina Heskel1, Ayesha Butt2, Alexander Pine2, Alfred Lee2. 1Yale School of Medicine, Dept. of Internal Medicine, New Haven, CT, USA. 2Yale School of Medicine, Dept. of Hematology, New Haven, CT, USA


10:57

THE HEPARIN NEUTRALIZATION STEP OF ELISA CAN BE REDUNDANT FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) TESTING
Xiangring He1, 2, Isabella K He3. 1University Hospitals of Cleveland, Cleveland, OH, USA. 2Case Western Reserve University, Cleveland, OH, USA. 3Northwestern University, Evanston, IL, USA


11:09

DEVELOPMENT OF A MODIFIED BETHESDA ASSAY FOR DETERMINING THE PRESENCE OF ANTIDRUG ANTIBODIES TO EMICIZUMAB
Hande Kizilocak1, Joshua Brown2, Desiree Tan-Castillo2, Guy Young1, 3. 1Children's Hospital Los Angeles, Hemostasis and Thrombosis Center, Los Angeles, CA, USA. 2Children, Los Angeles, CA, USA. 3University of Southern California, Keck School of Medicine, Los Angeles, CA, USA


11:21

ANALYSIS OF GENETIC MUTATIONS AND FACTOR VIII ASSAY DISCREPANCY AMONG FEMALE CARRIERS OF HEMOPHILIA A
Joanna M. Larson1, 2, Katherine E. Addy1, 2, Emma X. Li1, 2, John M. Hancock1, 2, 3, Natalie A. Montanez1, 2, Miguel A. Escobar1, 2, 3. 1Gulf States Hemophilia and Throbophilia Center, Houston, TX, USA. 2Department of Pediatrics, The University of Texas Health Science Center at Houston (UTHealth, Houston), Memorial Hermann, Texas Medical Center, Houston, TX, USA. 3Department of Internal Medicine, The University of Texas Health Science Center at Houston (UTHealth, Houston), Memorial Hermann, Texas Medical Center Houston, TX, Houston, TX, USA

12:00 - 1:00 PM
SATELLITE SYMPOSIUM
HELP CRACK THE CASE! A HEMOPHILIA A MYSTERY GAME AND AFTERNOON OF DISCUSSION (SPONSORED BY GENENTECH)
Chicago Ballroom IX-X

Genentech invites you to Help Crack the Case! in a fun-filled interactive mystery game showat this year's THSNA symposium. You'll hear from real patients and caregivers to find out just who's right for a subcutaneous prophylaxis option, and play along with our expert contestant, Dr. Michael Silvey. Throughout our game show, well explore considerations for identifying potential patients and learn more about the different patient types. You may be surprised at who these typical patients turn out to be! Plus, youll have an opportunity to have your questions answered in our live Q&A session. We look forward to seeing you there!



LONG-TERM MONITORING OF CLINICAL EFFICACY AND SAFETY PARAMETERS FOR INVESTIGATIONAL HEMOPHILIA GENE THERAPY (SPONSORED BY PFIZER)
Chicago Ballroom VI

This symposium will discuss the importance of patient monitoring both in the short- and long-term, exploring the variables that need to be considered in order to assess clinical efficacy and safety parameters of gene therapy. Presenters of this symposium will explore the practicalities of monitoring these parameters, focusing on coagulation assays and liver investigations, and review the questions that need to be addressed in the future in order to further our understanding of the mechanisms underlying this potential therapeutic approach. Gene therapy for the treatment of hemophilia is investigational. There are no gene therapies currently approved in the US for hemophilia.


1:15 - 2:45 PM
THROMBOSIS / LABORATORY
ECMO AND HEMOSTASIS
Chair/Organizer: Nicole Zantek, Leo Brandao
Chicago Ballroom VII


1:15

ANTICOAGULATION MONITORING AND ANTITHROMBIN III SUPPLEMENTATION IN ECMO
William Dager. University of California, Davis Medical Center


1:40

ECMO AND PEDIATRICS
Asavari Kamerkar. Children's Hospital Los Angeles


2:05

UNDERSTANDING AND UTILIZATION OF TEG/ROTEM (THROMBOELASTROGRAPHY)
Oksana Volod. Cedars Sinai


2:30

Q&A.

1:15 - 2:45 PM
BASIC SCIENCE
PROCOAGULANT BIOLOGY IN SICKLE CELL DISEASE
Chair/Organizer: Bryce Kerlin, Shannon Meeks
Sheraton Ballroom IV-V


1:15

ENDOTHELIAL THROMBIN - PAR1 SIGNALING AXIS IN SICKLE CELL DISEASE
Rafal Pawlinski. University of North Carolina at Chapel Hill


1:40

PLATELET-MEDIATED CONTRIBUTIONS TO HGB SS PATHOBIOLOGY
Sruti Shiva. Universitoy of Pittsburgh


2:05

EXTRACELLULAR VESICLES DISRUPT ENDOTHELIAL BARRIER FUNCTION IN SICKLE CELL
Eric Beyer. University of Chicago


2:30

Q&A.

1:15 - 2:45 PM
HEMOSTASIS
PSYCHOSOCIAL ASPECTS OF BLEEDING DISORDERS
Chair/Organizer: Lena Volland, Michael Recht
Sheraton Ballroom I-III


INTRODUCTION VIDEO.


1:15

IMPACT OF HEAVY MENSTRUAL BLEEDING AND BLOOD DISORDERS ON QUALITY OF LIFE
Patricia Huguelet. University of Colorado School of Medicine and Children's Hospital Colorado


1:40

HEMATOLOGIC ISSUES IN TRANSGENDER PATIENTS
Joseph Shatzel. Cincinnati Children's Hospital Medical Center


2:05

DEPRESSION AND SUICIDALITY IN BLEEDING DISORDER COMMUNITY
Maria Iannone. Arizona Hemophilia and Thrombosis Center


2:30

Q&A.

2:45 - 3:45 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB


A1. ANTICOAGULATION CLINICS


201

ADOPTION OF AN ELECTRONIC HEALTH RECORD TOOL TO PROMOTE VENOUS THROMBOEMBOLISM RISK ASSESSMENT FOR HOSPITAL MEDICINE PATIENTS
Grace E. Eisenbiegler1, Katherine Wilkinson3, Rachel K. McEntee1, 2, Allen B. Repp1, 2, Neil A. Zakai1, 2, 3, Preetika Muthukrishnan1, 2. 1University of Vermont Medical Center, Burlington, VT, USA. 2Department of Medicine, University of Vermont Larner College of Medicine, Burlington, VT, USA. 3Department of Pathology and Laboratory Medicine Larner College of Medicine, Burlington, VT, USA


A2. PLATELET ACTIVATION AND BIOCHEMISTRY


202

DELETION OF MITOCHONDRIAL ENZYME PYRUVATE DEHYDROGENASE KINASES (PDK2 AND PDK4) INHIBITS PLATELET FUNCTION AND ARTERIAL THROMBOSIS
Gagan D. Flora, Manasa K. Nayak, Madankumar Ghatge, Anil K. Chauhan. Division of Hematology/Oncology, University of Iowa, Iowa City, IA, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


203

INFUSED HUMAN MEGAKARYOCYTES IN MICE SUPPORT A UNIQUE ROLE OF THE PULMONARY VASCULATURE IN THROMBOPOIESIS
Hyunjun Kim1, Danuta Jarocha1, Ian Johnston1, Hyun Sook Ahn1, Deborah French1, Lubica Rauova1, 2, Mortimer Poncz1, 2. 1Children's Hospital of Philadelphia, Philadelphia, PA, USA. 2University of Pennsylvania, Philadelphia, PA, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


204

HEMOPHILIA A CARRIERS COMPARED WITH THE GENERAL FEMALE POPULATION: US ANALYSIS OF HEALTHCARE BURDEN
Katharine Batt1, Maja Kuharic2, 3, Shan Xing3, Sepehr Farahbakhshian3, Jorge Caicedo3, Sreya Chakladar4, Riddhi Markan4, Michael Bullano3. 1Sprouts Consulting Ltd, Raleigh, NC, USA. 2Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL, USA. 3Takeda Development Center Americas, Inc, Lexington, MA, USA. 4Complete HEOR Solutions, New Wales, PA, USA


205

RISK FACTORS OF VENOUS THROMBOEMBOLISM IN ELDERLY PATIENTS WITH ACUTE LEUKEMIA
Ambarina S. Faiz, Claire S. Philipp. Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA


206

HEPARIN ACTIVATION OF PROTEIN Z-DEPENDENT PROTEASE INHIBITOR (ZPI) ALLOSTERICALLY BLOCKS PROTEIN Z ACTIVATION THROUGH AN EXTENDED HEPARIN BINDING SITE
Xin Huang, Richard Swanson, Steven T. Olson. University of Illinois Chicago, Chicago, IL, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


207

HEMOSTATIC EFFICACY OF RECOMBINANT FACTOR VII PRODUCT EPTACOG BETA FOR BLEEDING MANAGEMENT: REAL-WORLD EXPERIENCE OF PATIENTS WITH HEMOPHILIA A AND B WITH INHIBITORS
Glaivy Batsuli1, Duc Q. Tran2, Guy Young3, Osman Khan4, Robert F. Sidonio1. 1Aflac Cancer and Blood Disorders Center of Children, Atlanta, GA, USA. 2Emory University, Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Atlanta, GA, USA. 3Children, Los Angeles, CA, USA. 4University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA


208

REAL-WORLD EFFECTIVENESS OF DAMOCTOCOG ALFA PEGOL IN MILD AND MODERATE HEMOPHILIA A PATIENTS AGED 12 YEARS AND OLDER IN THE ATHNDATASET
Martin Chandler1, Lena Charafi2, Thomas Moulton2, Michael Recht1. 1American Thrombosis a Hemostasis Network, Rochester, NY, USA. 2Bayer, Whippany, NJ, USA


209

HEREDITARY FACTOR X DEFICIENCY BURDEN OF DISEASE AND IMPACT ON QUALITY OF LIFE IN PATIENTS AND CAREGIVERS: INTERIM FINDINGS FROM THE HEREDITARY FACTOR X DEFICIENCY IN AMERICA SURVEY
Kim Clark1, Shirley P Huang2, Richard H Stanford2, Brian Branchford3, 4, 5. 1Bio Products Laboratory USA, Inc, Durham, NC, USA. 2AESARA, Inc, Chapel Hill, NC, USA. 3Versiti Blood Research Institute, Milwaukee, WI, USA. 4Medical College of Wisconsin, Milwaukee, WI, USA. 5Children, Milwaukee, WI, USA


210

RIGHT ATRIAL THROMBUS INCIDENCE IN CHILDHOOD CANCER
Sara McElroy, Lauren E. Amos, Emily Cramer, Michael Silvey, Joy M. Fulbright. Children's Mercy Hospital, Kansas City, MO, USA


211

PERI-OPERATIVE ORTHOPEDIC MANAGEMENT OF A PATIENT WITH SEVERE HEMOPHILIA A AND A FACTOR VIII INHIBITOR ON EMICIZUMAB
Natasha S. Rupani1, Roy Khalife2, Alan Tinmouth2, Sarah Ward3, Michelle Sholzberg4, Jerry Teitel5. 1Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada. 2Division of Hematology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada. 3Division of Orthopaedic Surgery, Department of Surgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. 4Division of Hematology, Departments of Medicine and Laboratory Medicine a Pathobiology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. 5Division of Hematology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada


212

HETEROTOPIC OSSIFICATION IN HEMOPHILIA: AN UNANTICIPATED COMPLICATION FOLLOWING TRAUMATICALLY-INDUCED HEMATOMA
Bruno U. K. Steiner1, 2, Mark A. Krimmel1, Eric Y. Chang 3, Merel A. Timmer4, Lorene E. Schmaderer5, Jeffrey Kallberg6, Jessica Ovans7, Grace Hernandez8, Jezzamine Choi1, Rebecca Kruse-Jarres1, 2. 1Washington Center for Bleeding Disorders, Seattle, WA, USA. 2University of Washington, Seattle, WA, USA. 3University of California, San Diego, San Diego, CA, USA. 4University Medicine Center Utrecht, Utrecht, Netherlands. 5Nebraska Medicine, Omaha, NE, USA. 6University of Texas Health Center San Antonio, San Antonio, TX, USA. 7Children's Minnesota, Minneapolis, MN, USA. 8The Center for Inherited Blood Disorders, Orange, CA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


213

LEVELS OF HEPARIN INDUCED ANTI-PF4 ANTIBODIES AND ENDOGENOUS GLYCOSAMINOGLYCANS AND THEIR RELATIONSHIP WITH INFLAMMATORY BIOMARKERS IN PULMONARY EMBOLI PATIENTS.
Bulent Kantarcioglu1, Roland Kraemer2, Fakiha Siddiqui1, Debra Hoppensteadt1, Walter Jeske1, Amir Darki1, Jawed Fareed1. 1Loyola University Medical Center, MAYWOOD, IL, USA. 2University of Heidelberg, Heidelberg Germany


A8. ANTITHROMBOTIC THERAPY


214

INTERMEDIATE VS. THERAPEUTIC DOSE ANTICOAGULATION IN HOSPITALIZED PATIENTS WITH COVID-19: RESULTS FROM A SINGLE ACADEMIC CENTER (THE IMPACT TRIAL)
Maria T DeSancho1, Marina Loizou2. 1Weill Cornell Medicine, New York, NY, USA. 2Weill Cornell Medicine, New York, NY, USA


215

POSTOPERATIVE ANTICOAGULATION STRATEGIES IN CHILDREN UNDERGOING INTERVENTION FOR CONGENITAL PORTOSYSTEMIC SHUNTS
Abraham Haimed, Sherif Badawy, Caroline Lemoine, Riccardo Superina, Rukhmi Bhat. Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA


216

ANTICOAGULATION QUALITY, EFFICACY, AND SAFETY OF EXTEMPORANEOUS LIQUID WARFARIN IN CHILDREN
Hayley Hansen, Kelly Heilman, Yaser Diab. Children's National Hospital, Washington, DC, USA


217

ENDOGENOUS HEPARIN LIKE GLYCOSAMINOGLYCAN IN VARIOUS DISEASES AS MEASURED BY A FLUORESCENCE QUENCHING METHOD
Siddharth Mehrotra1, Joseph Lewis1, Fakiha Siddiqui1, Alfonso Tafur2, Bulent Kantarcioglu1, Debra Hoppensteadt1, Walter Jeske1, Jawed Fareed1, Roland Kraemer3. 1Loyola University Medical Center, MAYWOOD, IL, USA. 2North Shore Health Systems, Evanston, IL. 3University of Heidleberg, Heidelberg Germany


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


218

PREVALENCE AND RISK FACTORS FOR PULMONARY EMBOLISM IN CHILDREN WITH SICKLE CELL DISEASE: AN INSTITUTIONAL COHORT STUDY
Natasha Bala, Stanek Joseph, Rodriguez Vilmarie, Villella Anthony. Nationwide Children's Hospital, Columbus, OH, USA

3:45 - 5:15 PM
HEMOSTASIS / LABORATORY
DIAGNOSIS AND MANAGEMENT OF VON WILLEBRAND DISEASE
Chair/Organizer: Marian Rollins-Raval, Karen Moser
Chicago Ballroom VII


3:45

NEW RECOMMENDATIONS FOR DIAGNOSIS OF VWD FROM THE INTERNATIONAL GUIDELINES
Robert Sidonio. Aflac Cancer and Blood Disorders and Emory University


4:10

VWD IN WOMEN
Maha Othman. Queen's University


4:35

ACQUIRED VWD: DIAGNOSIS AND MANAGEMENT
Kristi Smock. University of Utah and ARUP Laboratories


5:00

Q&A.

3:45 - 5:15 PM
BASIC SCIENCE
INFLAMMATION AND HEMOSTASIS
Chair/Organizer: Bryce Kerlin, Deirdre Nolfi-Donegan
Sheraton Ballroom IV-V


3:45

FIBRINOGEN AND S. AUREUS INFECTION
Matthew Flick. University of North Carolina at Chapel Hill


4:10

PLATELET-NEUTROPHIL CROSSTALK IN SYSTEMIC SCLEROSIS
Roxane Darbousset. Boston children's hospital


4:35

MECHANISMS LINKING FIBRINOGEN TO INFLAMMATORY COLITIS
Joseph Palumbo. Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine


5:00

Q&A.

3:45 - 5:15 PM
THROMBOSIS
THE CHANGING ROLE OF THE ANTICOAGULATION SERVICE
Chair/Organizer: Vinai Bhagirath, Gary Woods
Sheraton Ballroom I-III


3:45

ARE ANTICOAGULATION CLINICS THE NEXT MEDICAL DINOSAUR?
Elizabeth Renner. Michigan Medicine


4:10

ANTICOAGULATION AND PEDIATRICS: CONSIDERATIONS ACROSS CARE SETTINGS
Jennifer Meldau. Childrens National Hospital


4:35

ANTICOAGULATION MODELS OF CARE IN THE INPATIENT SETTING
Gary Woods. Children's Healthcare of Atlanta and Emory University


5:00

Q&A.

5:15 - 6:00 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB


A1. ANTICOAGULATION CLINICS


301

EVALUATION OF CARE FOR PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AT AN ANTICOAGULATION MANAGEMENT CLINIC “CAPS-AMC”
Jennifer Pitman1, 2, Alison Bond1, 2, Barbara Huth1, Rita Selby1, 2, William Geerts1, 2. 1Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 2University of Toronto, Toronto, ON, Canada


A2. PLATELET ACTIVATION AND BIOCHEMISTRY


302

DIRECT INHIBITION OF THE Gα13-P115RHOGEF INTERACTION BY THE INTEGRIN β3 SUBUNIT AND ITS ROLE IN REGULATING EXOCYTOSIS IN PLATELETS.
Yaping Zhang, Xiaojuan Zhao, Bo Shen, yanyan Bai, Claire Chang, Aleksandra Stojanovic, Randal A Skidgel, Ni Cheng, Xiaoping Du. 1Department of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, chicago, IL, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


303

VALIDATION OF A NOVEL ADAMTS13 ASSAY FOR CHARACTERIZATION OF PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA
J. Cameron Barton, Frida Miranda, Cooper Anderson, Joshua Muia. Oklahoma State University Center for Health Sciences, Tulsa, OK, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


304

THROMBOMODULIN SENSITIVITY DECREASES IN THROMBIN GENERATION ASSAYS IN THE EARLY POSTPARTUM PERIOD
Maria Cristina Bravo1, Kelley C McLean2, Matthew T Gissel1, Ira M Bernstein2, Thomas Orfeo1. 1University of Vermont, Department of Biochemistry, Colchester, VT, USA. 2University of Vermont Medical Center, Department of Obstetrics, Gynecology, And Reproductive Sciences, Burlington, VT, USA


305

PLASMINOGEN REPLACEMENT THERAPY FOR THE TREATMENT OF PATIENTS WITH CONGENITAL PLASMINOGEN DEFICIENCY: RESULTS FROM THE PHASE 2/3 STUDY
Amy D Shapiro1, Per M Sandset2, Joseph M Parker3, Karen Thibaudeau4, Prasad Mathew4, 5, Erin Weigel6, Charles Nakar1. 1Indiana Hemophilia a Thrombosis Center, Inc, Indianapolis, IN, USA. 2Oslo University Hospital, Oslo, Norway. 3Prometic/Liminal Biosciences Inc, Laval, QC, Canada. 4Global Medical AffairsKedrion SpA, Lucca, Italy. 5Presbyterian Hospital, Albuquerque, NM, USA. 6Kedrion BioPharma, Fort Lee, NJ, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


306

COMPARISON OF INFLAMMATORY BIOMARKERS BETWEEN SARS-COV-2 VACCINATED AND UNVACCINATED SUBJECTS
Nusrat Jabeen1, Anusha Amanullah2, Mushtaq Hussain2, Bulent Kantarcioglu1, Fakiha Siddiqui1, Jawed Fareed1. 1University of Karachi, Department of Microbiology, Karachi Pakistan. 2Dow University of health Sciences, Dow College of Biotechnology, Karachi Pakistan. 3Loyola University Medical Center, Maywood, IL, USA


307

PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, PHARMACOKINETICS, IMMUNOGENICITY AND SAFETY OF VON WILLEBRAND FACTOR/FACTOR VIII CONCENTRATE IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDER 6 YEARS OF AGE
Akshat Jain1, Tarja-Elina Weisz2, Cristina Solomon3, Sylvia Werner2. 1Loma Linda University School of Medicine, Loma Linda, CA, USA. 2Octapharma Pharmazeutika Produktionsges. m. b. H, Vienna, Austria. 3Octapharma AG, Lachen Switzerland


308

THROMBOTIC COMPLICATIONS IN PATIENTS WITH FACTOR V LEIDEN AND COVID-19: INSIGHTS FROM THE CORONA-VTE NETWORK
Candrika D. Khairani1, 2, Galit Frydman3, Barry Berger3, Rachel P. Rosovsky4, Antoine Bejjani1, 2, Nicole Porio1, 2, Samuel Z. Goldhaber1, 2, Gregory Piazza1, 2. 1Thrombosis Research Group, Brigham and Women, Boston, MA, USA. 2Cardiovascular Medicine Division, Brigham and Women, Boston, MA, USA. 3Coagulo Medical Technologies, Inc, Auburndale, MA, USA. 4Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA


309

POST-MARKETING OBSERVATIONAL STUDY OF THE SAFETY AND EFFICACY OF FIBRINOGEN CONCENTRATE IN CONGENITAL FIBRINOGEN DEFICIENCY IN PATIENTS OF ALL AGES
Flora Peyvandi1, 2, Gita Pezeshki3, Cristina Solomon4, Sylvia Werner3. 1Fondazione IRCCS Ca, Milan, Italy. 2Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Milan, Italy. 3Octapharma USA, Paramus, NJ, USA. 4Octapharma AG, Lachen, Switzerland


310

GENETICS INFLUENCE THE ABILITY TO FORM NEUTRALIZING ANTIBODIES TO FACTOR VIII THROUGH A GERMINAL CENTER RESPONSE
Seema R Patel1, Taran Lundgren1, 2, Wallace Hunter Baldwin1, Courtney Cox1, Ernest T Parker1, Ryan P Jajosky3, Patricia E Zerra1, 4, Cassandra Josephson1, Christopher Doering1, Sean R Stowell3, Shannon L Meeks1. 1Aflac Cancer and Blood Disorders Center, Children, Atlanta, GA, USA. 2Graduate Program in Molecular and Systems Pharmacology, Laney Graduate School, Emory University School of Medicine, Atlanta, GA, USA. 3Brigham and Women, Boston, MA, USA. 4Center for Transfusion Medicine and Cellular Therapies, Department of Laboratory Medicine and Pathology, Emory University School of Medicine, Atlanta, GA, USA


311

REAL-WORLD EFFECTIVENESS OF OCTOCOG ALFA TO TREAT HEMOPHILIA A IN JAPAN AND THE UNITED STATES
Michael Recht1, Ei Kinai2, Masashi Taki3, Sayaka Tachikawa4, Ryan Farej5, Thomas Moulton5, Midori Shima6, Martin Chandler1, Katsuyuki Fukutake2, 7. 1American Thrombosis a Hemostasis Network, Rochester, NY, USA. 2Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan. 3Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki City, Japan. 4Bayer Yakuhin, Ltd, Osaka, Japan. 5Bayer U. S. LLC, Whippany, NJ, USA. 6Department of Pediatrics, Nara Medical University, Nara, Japan. 7Department of Blood Coagulation, Ogikubo Hospital, Suginami City, Japan


312

SUCCESSFUL USE OF EPTACOG BETA PROPHYLAXIS IN AN ADOLESCENT WITH SEVERE HEMOPHILIA B WITH HIGH-TITER INHIBITOR RESULTING IN DECREASED BLEEDING EPISODES AND COST OF TREATMENT
Kimberley Youkhana, Yasmina Abajas. University of North Carolina Blood Research Center, Chapel Hill, NC, USA


313

LONGITUDINAL EFFICACY AND SAFETY OF N9-GP FOR PROPHYLAXIS AND BLEED CONTROL IN US PATIENTS
Guy Young1, Miguel Escobar2, Ayesha Zia3, Pernille Hojlund Nielsen4, Adam R Wufsus5, Laura Sedita Alaimo5, Allison P Wheeler6. 1University of Southern California Keck School of Medicine, Los Angeles, CA, USA. 2University of Texas Health Science Center, Houston, TX, USA. 3UT Southwestern Medical Center, Dallas, TX, USA. 4Novo Nordisk A/S, Soborg, Denmark. 5Novo Nordisk Inc, Plainsboro, NJ, USA. 6Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS


314

FEW PATIENTS WITH LIVEDOID VASCULOPATHY DEMONSTRATE COMPLEMENT DYSREGULATION IN A FUNCTIONAL ASSAY
Harish Eswaran1, Shruti Chaturvedi2, Paul Googe3, Gloria Gerber2, Xiang-Zuo Pan2, Robert Brodsky2, Stephan Moll4. 1Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 2Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 4Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA


A8. ANTITHROMBOTIC THERAPY


315

MEDICATION LIST ACCURACY AND GUIDELINE CONCORDANCE OF PRIMARY PREVENTION ASPIRIN USE
Naina Chipalkatti1, Geoff Barnes2, Linda Bashaw1, Adam Davie1, Jennifer Griggs3, Molly Harrod4, Jacob Kurlander5, Christine Medaugh6, Rebeca Packard7, Suman Sood3, Liz Spranger1, Sarah Vordenberg8, Jordan Schaefer3. 1Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, USA. 3Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA. 4Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. 5Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA. 6Department of Family Medicine, University of Michigan, Ann Arbor, MI, USA. 7Health Information Technology a Services, University of Michigan, Ann Arbor, MI, USA. 8College of Pharmacy, University of Michigan, Ann Arbor, MI, USA


316

TISSUE FACTOR PATHWAY INHIBITOR (TFPI) RELEASE BY BOVINE, OVINE, PORCINE UNFRACTIONATED HEPARINS AND SULODEXIDE IN PRIMATES.
Jawed Fareed1, Ahmed Kouta1, Emily Bontekoe1, Richard Duff1, Walter Jeske1, Debra Hoppensteadt1, Mark Jaradeh1, Yiming Yao2, Guy Olson1. 1Loyola University Medical Center, Maywood, IL, USA. 2Ronnsi Pharma, Suzhou China


317

AUTOMATED THROMBIN GENERATION ASSAY PERFORMANCE IN PEDIATRIC PATIENTS TREATED WITH VARIABLE ANTICOAGULANTS: A PILOT STUDY.
Vadim Kostousov, Karen Bruzdoski, Amir Navaei, Lisa Hensch, Shiu-Ki Hui, Jun Teruya. Texas Children's Hospital, Houston, TX, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


318

NATIONAL ECONOMIC BURDEN OF ADULTS WITH SEVERE HEMOPHILIA A MANAGED WITH PROPHYLAXIS IN THE UNITED STATES
Taiji Wang1, Er Chen2, Catherine Regan3, Keziah Cook1, Noam Kirson4, Edmund Pezalla5, Mark Skinner6, 7. 1Analysis Group Inc, Menlo Park, CA, USA. 2BioMarin Pharmaceutical Inc, Novato, CA, USA. 3Analysis Group Inc, San Francisco, CA, USA. 4Analysis Group Inc, Boston, MA, USA. 5Enlightenment Bioconsult, LLC, Daytona Beach, FL, USA. 6Institute for Policy Advancement Ltd, Washington DC United States. 7McMaster University, Hamilton, ON, USA

6:00 - 7:15 PM
SATELLITE SYMPOSIUM
2022 DINNER SYMPOSIUM: ADVANCING NEW FRONTIERS IN HEMOPHILIA MANAGEMENT (SPONSORED BY BIOMARIN PHARMACEUTICAL INC. )
Chicago Ballroom IX-X

Recognizing the history and reasoning for exploring gene therapy in lifelong conditions like hemophilia will be a focus of this conversation with the experts. During this dinner symposium, attendees will be part of expert discussions on topics relating to liver health in the context of liver-directed gene therapy, follow-up care and surveillance registries in patients with hemophilia, and practical logistics for establishing and maintaining successful gene therapy transfer clinic operations. The four leading experts will provide updates on these cutting-edge, scientific topics followed by an open panel discussion with attendees. We hope that you will join us.



THE FIRST AND ONLY FDA-APPROVED AGENT FOR REVERSAL OF FXA INHIBITOR ACTIVITY IN PATIENTS WITH LIFE-THREATENING OR UNCONTROLLED BLEEDING (SPONSORED BY ASTRAZENECA)
Chicago Ballroom VI

This program will discuss the burden of life-threatening bleeds related to FXa inhibitors, and focus on the mechanism of action, efficacy, and safety of a reversal agent indicated for patients treated with anticoagulants who have life-threatening bleeding.


7:30 - 9:30 PM
POSTER SESSION
VIRTUAL POSTERS (ON-DEMAND ONLY)
Virtual Meeting System


RIVAROXABAN FOR THROMBOSIS IN PEDIATRIC PATIENTS: A RETROSPECTIVE OBSERVATIONAL STUDY FROM THE LOW/MIDDLE INCOME SETTING.
Aimen Mehmood, Bushra Moiz, Zehra Fadoo, Asim Belgaumi, Naureen Mushtaq, Sadaf Altaf. Aga Khan University, Karachi, Pakistan


“DOES MY PATIENT HAVE HEPARIN-INDUCED THROMBOCYTOPENIA? THERE SHOULD BE AN APP FOR THAT. ”
Frederic Allemand, Matthieu Stoll. Emosis, Illkirch-Graffenstaden, France


SURVIVAL OUTCOMES FOLLOWING INFERIOR VENA CAVA FILTER INSERTION IN CANCER PATIENTS; A COMPREHENSIVE CANCER CENTER EXPERIENCE.
Hikmat Abdel-Razeq1, Faris Tamimi1, Rashid Abdel-Razeq1, Ahmad Naser1, Rama Al Masri2, Jaafar Bani Issa1, Baha' Sharaf1, Osama Salama1, Rayan Bater1. 1King Hussein Cancer Center, Amman, Jordan. 2Istishari Hospital, Amman, Jordan


CHARACTERIZING RE-ADMISSION, BLEEDING, AND THROMBOTIC EVENTS IN COVID-19 PATIENTS RECEIVING ANTICOAGULATION THERAPY: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS
Tony Zhuang1, Rachel Mather1, Smitha John2, Judy Gichoya1, Alyssa Utz1, Mikhail Akbashev1. 1Emory University School of Medicine, Atlanta, GA, USA. 2Morehouse School of Medicine, Atlanta, GA, USA


A RETROSPECTIVE REVIEW OF INFERIOR VENA CAVA (IVC) FILTER USE
Yuxin Bai1, Stephanie Fontyn1, Samantha Bolger1, Kaity Greco1, Caroline Hamm1, 2, Andrea Cervi1, 2. 1Schulich School of Medicine a Dentistry, London, ON, Canada. 2Department of Medical Oncology, Windsor Regional Cancer Center, Windsor, ON, Canada


THROMBOELASTOGRAPHY TRIGGERED BY CONTACT PATHWAY ACTIVATION REQUIRES PLATELET INTEGRIN ACTIVATION AND CONTRACTION BUT NOT MAJOR PLATELET SIGNALING PATHWAYS
Tanvi Rudran, Robert H Lee, Silvio Antoniak, Alisa S Wolberg, Wolfgang Bergmeier. University of North Carolina, Chapel Hill, NC, USA


ALTERATIONS IN THE PLATELET COUNT AND MORTALITY DUE TO COVID-19 DURING THE FIRST AND SECOND WAVE IN PERUVIANS: A RETROSPECTIVE COHORT IN A NATIONAL REFERENCE CENTER.
Rafael Pichardo-Rodriguez1, Willy Pena-Oscuvilca2, Oscar Ruiz-Franco2, Fausto Garmendia-Lorena2. 1Research Institute in Biomedical Sciences (INICIB). Ricardo Palma University, Lima, Peru. 2Clinical Research Institute, Lima, Peru


PROFILING OF THROMBOINFLAMMATORY BIOMARKERS: A DEPICTION OF THE ENDOTHELIAL PATHOGENESIS OF ATRIAL FIBRILLATION
Gabriel Dungan1, Ameer Odeh1, Emily Bontekoe1, Fakiha Siddiqui1, Debra Hoppensteadt1, Omer Iqbal1, Jawed Fareed1, Guy Olson1, Mushabbar Syed2. 1Loyola University Medical Center, Department of Pathology and Laboratory Medicine, Maywood, IL, USA. 2Loyola University Medical Center, Department of Cardiology, Maywood, IL, USA


GENERATION OF ANTICOAGULANT RNA APTAMERS TARGETING COFACTORS THAT INHIBIT CLOTTING IN NORMAL AND COVID-19 PATIENT SAMPLES
Haixiang Yu1, Erin Soule1, Lyra Olson1, Ibtehaj Naqvi1, Shekhar Kumar2, Juliana Layzer1, Sriram Krishnaswamy2, Bruce Sullenger1. 1Duke University, Department of Surgery, Durham, NC, USA. 2Children, Philadelphia, PA, USA


REDUCED TIME TO GASTROINTESTINAL PROCEDURE AFTER WARFARIN REVERSAL WITH FOUR FACTOR PROTHROMBIN COMPLEX CONCENTRATE (4F-PCC) AS COMPARED TO PLASMA IN PATIENTS WITH GASTROINTESTINAL BLEEDING
Hannah L McRae1, Hannah Spector1, Tanzy Love2, Deborah Sturpe3, Kalynn Northam4, Majed A Refaai1. 1Department of Pathology and Laboratory Medicine, Transfusion Medicine Division, University of Rochester Medical Center, Rochester, NY, USA. 2Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA. 3Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA. 4Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA


ONCE DAILY DOSING OF PROTEIN C CONCENTRATE FOR SEVERE PROTEIN C DEFICIENCY
Melissa Verdolotti, Montcrieff Caitlin. Rhode Island Hemostasis a Thrombosis Center, Providence, RI, USA


EVALUATING THE ROLE OF ROTATIONAL THROMBOELASTOMETRY (ROTEM) AS A PREDICTOR FOR POSTPARTUM HEMORRHAGE
Radia Ksayer, Karam Zakharia, Cindy Leissinger, Maissaa Janbain. Tulane University, New Orleans, LA, USA


SINGLE-NUCLEOTIDE POLYMORPHISMS IN THE ABO BLOOD GROUP LOCUS ARE PLEIOTROPICALLY ASSOCIATED WITH THE PLASMA LEVELS OF FACTOR VIII COAGULANT ACTIVITY AND VON WILLEBRAND FACTOR ANTIGEN IN MEXICAN AMERICANS OF SOUTH TEXAS
Shuchita Jhaveri1, Vincent P. Diego2, 3, Marcio A. Almeida2, 3, Hoang A. Nguyen1, Juan M. Peralta2, 3, Joanne E. Curran2, 3, Donna Lehman4, Ralph DeFronzo4, Miguel A. Escobar5, Raja Rajalingam6, Jerry S. Powell7, 8, Sarah Williams-Blangero2, 3, Ravindranath Duggirala2, 3, John Blangero2, 3, Tom Howard2, 3, 7, 9. 1University of Texas Rio Grande Valley (UTRGV) School of Medicine (SOM), Edinburg, TX, USA. 2Department of Human Genetics, UTRGV SOM, Brownsville, TX, USA. 3South Texas Diabetes and Obesity Institute, UTRGV SOM, Brownsville, TX, USA. 4University of Texas Health Science Center at San Antonio SOM, San Antonio, TX, USA. 5Division of Hematology and Oncology, Department of Internal Medicine, McGovern SOM, University of Texas Health Science Center at Houston, Houston, TX, USA. 6Immunogenetics and Transplantation Laboratory, Department of Surgery, School of Medicine, University of California at San Francisco, San Francisco, CA, USA. 7Haplogenics Corporation, Brownsville, TX, USA. 8Division of Hematology and Oncology, Department of Medicine, SOM, University of California at Davis, Davis, CA, USA. 9Department of Pathology and Laboratory Medicine, VA Texas Valley Coastal Bend Health Care System, Harlingen, TX, USA


FABRICATION OF A PHYSIOLOGICALLY RELEVANT FLUORESCENTLY LABELED CLOT IN A CHANDLER LOOP
Ziqian Zeng1, Alexei Christodoulides2, Nathan J Alves1, 2. 1Purdue University - Department of Biomedical Engineering, West Lafayette, IN, USA. 2Indiana University School of Medicine - Department of Emergency Medicine, Indianapolis, IN, USA


FACTOR VII ACTIVATING PROTEASE DOES NOT PREDICT THE DISABILITY OF ISCHEMIC STROKE PATIENTS
Artur Slomka1, Iga Kwiatkowska1, Malgorzata Wiszniewska2, Ewa Zekanowska1. 1Department of Pathophysiology, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum, Bydgoszcz, Poland. 2Stanislaw Staszic Specialist Hospital, Neurology and Stroke Care Unit, Pila, Poland


HEMOSTASIS DISORDERS AND CORONAVIRUS DISEASE: EXPERIENCE OF THE HEMATOLOGY LABORATORY OF CHU IBN ROCHD OF CASABLANCA
Chaimaa Zirhi1, Hanaa Bencharef2, Bouchra Ifegh3, Bouchra Oukkache4. 1Hematology Laboratory, CHU Ibn Rochd Casablanca, Casablanca, Morocco. 2Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Casablanca, Morocco. 3Hematology Laboratory, CHU Ibn Rochd Casablanca, Casablanca, Morocco. 4Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Casablanca, Morocco


CHARACTERISTICS AND HEALTH CARE UTILIZATION AMONG PERSONS WITH INHERITED BLEEDING DISORDERS RECEIVING CARE OUTSIDE OF US HEMOPHILIA TREATMENT CENTERS: A COLLABORATION BETWEEN THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND TWO ACADEMIC MEDICAL CENTERS
Courtney D. Thornburg1, 2, Binh Le3, Vanessa R. Byams3, Meredith Oakley3, Kristin Byrne4, Ara Metjian5. 1Rady Children's Hospital San Diego, San Diego, CA, USA. 2UC San Diego, La Jolla, CA, USA. 3National Center on Birth Defects and Developmental Disabilities, Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4Duke University Health System, Durham, NC, USA. 5University of Colorado Anschutz Medical Center, Denver, CO, USA


ACQUIRED FACTOR XIII DEFICIENCY DETERMINES POSTOPERATIVE BLOOD LOSS
Emilie K. von Depka1, Carsten Detering1, Michael Boeker2, Mario von Depka1. 1Werlhof Institute, Hannover, Germany. 2Paracelsus Klinik am Silbersee, Langenhagen, Germany


SHARED DECISION-MAKING FOR HEMOPHILIA GENE THERAPY: PATIENT PERSPECTIVES AND EXPECTATIONS
Jacqueline Limjoco1, Hannah Reyes1, Jennifer Han1, 2, Courtney Thornburg1, 2. 1Rady Children's Hospital San Diego, San Diego, CA, USA. 2UC San Diego School of Medicine, La Jolla, CA, USA


LIGHT-CHAIN PARAPROTEINS IN COAGULATION ASSAYS AND THEIR CLINICAL ASSOCIATIONS: A REPORT OF 6 CASES
Jing Jin1, Steven Baker2, James Zehnder3. 1Department of Special Coagulation, Clinical Laboratories, Stanford Health Care, Palo Alto, CA, USA. 2Department of Pathology, University of Utah, Salt Lake city, UT, USA. 3Department of Pathology, School of Medicine, Stanford University, Stanford, CA, USA


THE ORIGIN OF FERRITIN REFERENCE INTERVALS: A SYSTEMATIC REVIEW
Judy Truong1, Kanza Naveed1, Daniel Beriault2, 3, David Lightfoot4, Michael Fralick5, Michelle Sholzberg6, 7, 8, 9. 1Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 2Division Head, Clinical Biochemistry, Department of Laboratory Medicine, St. Michael, Toronto, ON, Canada. 3Assistant Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 4Information Specialist, Health Sciences Library, St. Michael's Hospital, Toronto, ON, Canada. 5Clinician Scientist, Lenenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON, Canada. 6Head of the Division of Hematology-Oncology, St. Michael, Toronto, ON, Canada. 7Director of the Hematology-Oncology Clinical Research Group, St. Michael, Toronto, ON, Canada. 8Assistant Professor, University of Toronto, Toronto, ON, Canada. 9Associate Scientist, Li Ka Shing Knowledge Institute, Toronto, ON, Canada


THE ROLE OF EMICIZUMAB IN BLEED CONTROL IN PATIENTS WITH AQUIERED HEMOP0HILIA A
Karam Zakharia, Radia Ksayer, Cindy leissinger, Maissaa Janbain. Tulane University, New Orleans, LA, USA


SYNONYMOUS ADAMTS13 VARIANTS IMPACT MOLECULAR CHARACTERISTICS AND CONTRIBUTE TO VARIABILITY IN ACTIVE PROTEIN ABUNDANCE
Katarzyna /I Jankowska, Douglas Meyer, David /D Holcomb, Jacob Kames, Nobuko Katagiri, Chava Kimchi-Sarfaty. US Food and Drug Administration, Silver Spring, MD, USA


THE IMPACT OF OBESITY ON CHRONIC PAIN IN PATIENTS WITH HEMOPHILIA: A MULTICENTER RETROSPECTIVE ANALYSIS
Keerthy Joseph1, Adam Cuker2, 3, Skye Peltier4, Mark Reding5, Xiaoyan Han6, Allyson Pishko2. 1Department of Medicine, Mercy Catholic Medical Center, Darby, PA, USA. 2Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4American Thrombosis and Hemostasis Network, Rochester, NY, USA. 5Center for Bleeding and Clotting Disorders, University of Minnesota, Minneapolis, MN, USA. 6Department of Biostatistics, Epidemiology and Informatics (DBEI), Perelman School of Medicine, University of Pennsylvania, Philadlephia, PA, USA


ONCE-WEEKLY ADMINISTRATION OF NONACOG BETA PEGOL(N9-GP) IS ASSOCIATED WITH HIGH TREATMENT ADHERENCE AND REDUCTIONS IN ANNUALIZED BLEEDING RATES IN CHILDREN WITH HEMOPHILIA B
Manuel Carcao 1, Susan Kearney2, Allison Wheeler3, Chunduo Shen4, Helle Holst4, Ayesha Zia5. 1Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada. 2Center for Bleeding and Clotting Disorders, Children, Minneapolis, MN, USA. 3Vanderbilt University Medical Center, Nashville, TN, USA. 4Novo Nordisk, Copenhagen, Capital region, Denmark. 5Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA


NEUROCOGNITIVE AND NEUROLOGICAL OUTCOMES IN CHILDREN WITH HEMOPHILIA B ARE UNAFFECTED BY LONG-TERM EXPOSURE TO NONACOG BETA PEGOL (N9-GP)
Manuel Carcao1, Anthony KC Chan2, Allison P Wheeler3, Pernille Hojlund Nielsen4, Helle Holst4. 1Division of Hematology/Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada. 2Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada. 3Vanderbilt University Medical Center, Nashville, TN, USA. 4Novo Nordisk A/S, Copenhagen, Capital region, Denmark


CLINICAL OUTCOMES OF COVID-19 IN PATIENTS WITH VON WILLEBRAND DISEASE: A MULTICENTER DATABASE STUDY
Meric Mericliler1, 2, Ruchi Desai1, 2. 1Division of Hematology and Oncology, Virginia Commonwealth University, Richmond, VA, USA. 2Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA


FIRST NEUTRALIZING ANTIDRUG ANTIBODY TO EMICIZUMAB IN A PATIENT WITH SEVERE HEMOPHILIA A WITHOUT INHIBITORS
Michael F. Guerrera1, Hande Kizilocak2, Carly Varela1, 3, Christine Guelcher1, Lauren Godby3, Guy Young2. 1Children's National Hospital, Washington, DC, USA. 2Children's Hospital Los Angeles, Los Angeles, CA, USA. 3Pediatric Specialists of Virginia, Fairfax, VA, USA


CONTEMPORARY MANAGEMENT OF PREGNANT WOMEN WITH TYPE 1 VON WILLEBRAND DISEASE: A SINGLE-INSTITUTION RETROSPECTIVE STUDY
Ming Y Lim1, George M Rodgers1, Sara E Simonsen2. 1University of Utah Health, Salt Lake City, UT, USA. 2University of Utah College of Nursing, Salt Lake City, UT, USA


IMPACT OF ERYTHROCYTE-DERIVED MICROPARTICLES FROM SICKLE CELL DISEASE PATIENTS IN THE STEADY STATE ON THROMBIN GENERATION AND EFFECTS OF HYDROXYUREA TREATMENT
Patrick Van Dreden1, Aurelie Rousseau1, Ismail Elalamy2, Grigorios Gerotziafas2. 1Clinical Research Stago, Gennevilliers, France. 2APHP Hopital Tenon, Paris, France


PROFILE OF THROMBIN GENERATION ASSAY AND THROMBOELASTOMETRY TO IDENTIFY WOMEN WITH MODERATE AND SEVERE PREECLAMPSIA. THE ROADMAP-PREECLAMPSIA STUDY
Patrick Van Dreden1, 2, Elmina Lefkou3, Aurelie Rousseau1, Grigorios Gerotziafas2, 4. 1Clinical Research Diagnostica Stago, Gennevilliers, France. 2INSERM U938, Paris, France. 3Haematology Unit, Hippokration Hospital of Thessaloniki, Thessaloniki, Greece. 4Haematology-biology department Tenon hospital, Paris, France


BURDEN OF DISEASE IN POTENTIAL PROPHYLAXIS-ELIGIBLE PATIENTS WITH VON WILLEBRAND DISEASE: POST-HOC ANALYSIS OF THE “COST OF VON WILLEBRAND DISEASE ACROSS EUROPE, A SOCIOECONOMIC STUDY” (CVESS)
Ping Du1, George Morgan2, Sarah Brighton2, Francoise Truong Berthoz3, Nataliya Kemenyash3, Shawn X. Sun1. 1Takeda Development Center Americas, Inc, Cambridge, MA, USA. 2HCD Economics, Daresbury, United Kingdom. 3Takeda Pharmaceuticals International AG, Zurich, Switzerland


BIOLOGICAL DIAGNOSIS OF THROMBOPHILIA IN CHILDREN: EXPERIENCE OF THE HEMATOLOGY LABORATORY OF THE IBN ROCHD UNIVERSITY HOSPITAL IN CASABLANCA
Samy Ennachachibi1, 2, Hanaa Bencharef 1, 2, Bouchra Oukkache 1, 2. 1Hematology laboratory of CHU Ibn Rochd, Casablanca, Morocco. 2Hassan II University, Faculty of Medicine and Pharmacy of Casablanca, Casablanca, Morocco


OXIDATIVE STRESS BIOMARKERS AND THEIR RELEVANCE TO FATTY ACID-BINDING PROTEIN IN STAGE-V CHRONIC KIDNEY DISEASE PATIENTS ON HEMODIALYSIS
Divya Sridharan, Pranathi Karumanchi, Guy Olson. Loyola University of Chicago Stritch School of Medicine, Maywood, IL, USA


F5_6755A>G, A NONSYNONYMOUS SINGLE-NUCLEOTIDE VARIATIONTHATSUBSTITUTES GLYCINE FOR ASPARTATE AT RESIDUE 2, 194 IN THE PLASMA BLOOD CLOTTING PROTEIN FACTOR V, IS PLEIOTROPICALLY ASSOCIATED WITH REDUCED FACTOR V COAGULANT ACTIVITY AND A DECREASED FRAILTY INDEX
Hoang A. Nguyen1, Vincent P. Diego2, 3, Marcio A. Almeida2, 3, Shuchita Jhaveri1, Juan M. Peralta2, 3, Joanne E. Curran2, 3, Donna Lehman4, Ralph DeFronzo4, Miguel A. Escobar5, Raja Rajalingam6, Jerry S. Powell7, 8, Sarah Williams-Blangero2, 3, Ravindranath Duggirala2, 3, John Blangero2, 3, Tom Howard2, 3, 7, 9. 1University of Texas Rio Grande Valley (UTRGV) School of Medicine (SOM), Edinburg, TX, USA. 2Department of Human Genetics, UTRGV SOM, Brownsville, TX, USA. 3South Texas Diabetes and Obesity Institute, UTRGV SOM, Brownsville, TX, USA. 4University of Texas Health Science Center at San Antonio SOM, San Antonio, TX, USA. 5Division of Hematology and Oncology, Department of Internal Medicine, McGovern SOM, University of Texas Health Science Center at Houston, Houston, TX, USA. 6Immunogenetics and Transplantation Laboratory, Department of Surgery, School of Medicine, University of California at San Francisco, San Francisco, CA, USA. 7Haplogenics Corporation, Brownsville, TX, USA. 8Division of Hematology and Oncology, Department of Medicine, SOM, University of California at Davis, Davis, CA, USA. 9Department of Pathology and Laboratory Medicine, VA Texas Valley Coastal Bend Health Care System, Harlingen, TX, USA


NEUTROPHIL PHENOTYPES CORRELATE WITH NET RELEASE AND PHOSPHATIDYLSERINE EXPOSURE
Margaret H McKelvy, Madison G Chait, Madelaine E Duarte, Sanjay Khandelwal, Gowthami M Arepally, Grace M Lee. Division of Hematology, Duke University, Durham, NC, USA


CORRELATION OF NF-KB AND D-DIMER WITH THE INCIDENCE OF DEEP VEIN THROMBOSIS IN HIGH-RISK THROMBOSIS CANCER PATIENTS
Tri W Sukarnowati1, Budi Setiawan2, Daniel Rizqy1, Eko A Pangarsa2, Damai Santosa2, Catharina Suharti2. 1Trainee in Hematology-Medical Oncology, Internal Medicine Department, Faculty of Medicine Diponegoro University/Dr. Kariadi Hospital, Semarang, Indonesia. 2Hematology-Medical Oncology Division, Internal Medicine Department, Faculty of Medicine, Diponegoro University/Dr. Kariadi Hospital, Semarang, Indonesia


COMPARISON OF HEPARIN DOSAGE IN CRITICALLY ILL CHILDREN
Andrew Eckberg , Asavari Kamerkar, Eugene Laksana , Melissa Aczon, Randall Wetzel, David Ledbetter. Children's Hospital Los Angeles, Los Angeles, CA, USA


BLEEDING OUTCOMES AND MANAGEMENT OF SUPRATHERAPEUTIC EPISODES SECONDARY TO WARFARIN IN PEDIATRICS: A SINGLE CENTER 11-YEAR EXPERIENCE
Clay T Cohen1, HyoJeong Han1, Mark Zobeck1, Joseph A Spinner2, Jacquelyn M Powers1, YoungNa Lee-Kim1, Sarah E Sartain1. 1Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA. 2Department of Pediatrics, Division of Cardiology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA


BIO-EQUIVALENCE OF POTENCY ADJUSTEDAPPROVED HEPARIN SOLUTIONS COMPARED TOA NEWLY DEVELOPED HEPARIN SOLUTION.
Debra Hoppensteadt1, Walter Jeske1, Ambar Farooqui1, Ahmed Kouta1, Omer Iqbal1, Bulent Kantarcioglu1, Roland Kraemer2, Jawed Fareed1, Guy Olson1. 1Loyola Univerity Chicago, Maywood, IL, USA. 2University of Heidelberg, Heidelberg Germany


TECHNICAL FEASIBILITY AND CLINICAL EFFICACY OF ILIAC VEIN STENT PLACEMENT IN ADOLESCENTS WITH MAY-THURNER SYNDROME
Frederic J. Bertino1, 2, C. Matthew Hawkins1, 2, Gary Woods1, 3, Jay H. Shah1, 2, Darshan E. Variyam1, 2, Anne E. Gill1, 2. 1CHILDREN'S HEALTHCARE OF ATLANTA, ATLANTA, GA, USA. 2Emory University SOM Dept. of Radiology and Imaging Sciences, Division of Interventional Radiology and Image Guided Medicine, Atlanta, GA, USA. 3Emory University School of Medicine, Department of Pediatrics, Division of Hematology and Oncology, Atlanta, GA, USA


RETROSPECTIVE ANALYSIS OF HEREDITARY THROMBOPHILIA WORKUPS IN THE PEDIATRIC POPULATION OVER THREE YEARS: A SINGLE CENTER STUDY
Hannah L McRae, Alexa Turgeman, Majed A Refaai. Department of Pathology and Laboratory Medicine, Transfusion Medicine Division, Hemostasis and Thrombosis Unit, University of Rochester Medical Center, Rochester, NY, USA


INDIAN RECOMMENDATIONS ON ANTITHROMBOTIC MANAGEMENT FOR CHRONIC CORONARY SYNDROME: AN EXPERT CONSENSUS DELPHI STUDY
Kamal Sharma1, Jay Shah2, Prakash Hazra3, Jagdish Hiremath4, Varun Narain5, Ashwani Mehta6, Ajit Bhagwat7, Aziz Khan8, Govindan Unni9, Tiny Nair10, Ajay Mahajan11, Ajay Naik12, K Kannan13, Monotosh Panja14, Prasant Kumar Sahoo Sahoo15, Subash Manchanda6. 1Dr. Kamal Sharma Cardiology Clinic, Ahmedabad, India. 2HCG Hospitals, Krish Heart Care, Ahmedabad, India. 3AMRI Hospitals, Kolkata, India. 4Ruby Hall, Pune, India. 5Divine Heart and Multispeciality Hospital, Lucknow, India. 6Sir Gangaram Hospital, Delhi, India. 7Kamalnayan Bajaj Hospital, Aurangabad, India. 8Crescent Hospital and Heart Centre, Nagpur, India. 9Jubilee Mission Hospital, Thrissur, India. 10PRS Hospital, Trivandrum, India. 11Cardiocare Heart Clinic, Mumbai, India. 12CIMS Hospital, AHMEDABAD, India. 13Stanley Medical College, Chennai, India. 14Belle Vue Clinic and AMRI Hospital, Kolkata, India. 15Apollo Hospital, Bhubneshwar, India


VENOUS THROMBOEMBOLISM IN ADULT HOSPITALIZATIONS - UNITED STATES 2012-2019
Alys Adamski, Karon Abe, Nimia Reyes, Laura Schieve . Centers for Disease Control and Prevention, Atlanta, GA, USA


VAGINAL BLOOD LOSS: A PATIENT- AND MEDICAL TRAINEE-CENTERED MIXED-METHODS RESEARCH PROGRAM
Fartoon M Siad1, Romy Segall2, Andrea Lausman1, 3, Filomena Meffe1, 3, Carolyn Snider1, 4, Martina Trinkaus1, 5, Michelle Sholzberg1, 5. 1Department of Medicine, University of Toronto, Toronto, ON, Canada. 2Department of Medicine, Dalhousie University, Halifax, NS, Canada. 3Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada. 4Division of Emergency Medicine, University of Toronto, Toronto, ON, Canada. 5Division of Hematology and Oncology, St. Michael, Toronto, ON, Canada


VALIDATION OF PRODUCTION PROCESS OF THE FACTOR VIII COAGULATION
Nataliia Shurko, Taras Danysh , Svitlana Myliashkevich, Vasyl Novak. State institution, Lviv, Ukrenia


LOW INTENSITY HEPARIN INFUSION WAS ASSOCIATED WITH DECREASED MINOR BLEEDING AMONG PATIENTS WITH RECENT BLEEDING OR SURGERY, WITHOUT INCREASING THROMBOSIS.
Niaima/Y Geresu3, Melissa/P Patel1, Danielle/N Martin3, Lester/T Piri3, Michael/D Knauss1, Bradley/L Smith1, Tony/Z Zhuang2, Mikhail/Y Akbashev2, 1. 1Grady Health System, Atlanta, GA, USA. 2Emory University School of Medicine, Atlanta, GA, USA. 3Mercer College of Pharmacy, Atlanta, GA, USA


PATIENT-CENTRED CARE FOR WARFARIN MANAGEMENT: A PILOT STUDY TO TRANSITION CARE TO HIGH RISK PATIENTS
Tammy J Bungard, Micheal S McMurtry, Steven R Meyer, Bruce Ritchie, Ross T Tsuyuki. University of Alberta, Edmonton, AB, Canada


OPTIMIZATION OF STROKE PROPHYLAXIS FOR ATRIAL FIBRILLATION WITHIN CALGARY CO-OP: IMPACT OF A QUALITY IMPROVEMENT INITIATIVE
Tammy J Bungard1, Sonal Ejner2. 1University of Alberta, Edmonton, AB, Canada. 2Calgary Co-operative Association Limited, Calgary, AB, Canada